NasdaqGS - Delayed Quote • USD
Madrigal Pharmaceuticals, Inc. (MDGL)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:38 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 14 | 14 |
| Avg. Estimate | -6.3 | -6.62 | -23.48 | -14.46 |
| Low Estimate | -7.34 | -8.33 | -32.21 | -27.28 |
| High Estimate | -4.86 | -5.45 | -13.67 | -3.06 |
| Year Ago EPS | -4.23 | -4.69 | -19.99 | -23.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 11 | 12 | 11 |
| Avg. Estimate | -- | 4.33M | 89.05M | 379.66M |
| Low Estimate | -- | -- | 61.11M | 201.78M |
| High Estimate | -- | 15M | 112.4M | 509.22M |
| Year Ago Sales | -- | -- | -- | 89.05M |
| Sales Growth (year/est) | -- | -- | -- | 326.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.94 | -4.58 | -4.92 | -5.28 |
| EPS Actual | -4.23 | -4.69 | -5.34 | -5.68 |
| Difference | 0.71 | -0.11 | -0.42 | -0.4 |
| Surprise % | 14.40% | -2.40% | -8.50% | -7.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -6.3 | -6.62 | -23.48 | -14.46 |
| 7 Days Ago | -6.3 | -6.62 | -23.48 | -14.46 |
| 30 Days Ago | -6.3 | -6.62 | -23.48 | -14.46 |
| 60 Days Ago | -5.05 | -5.36 | -16.77 | -3.79 |
| 90 Days Ago | -5.6 | -5.53 | -15.97 | 0.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MDGL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -48.90% | -- | -- | 1.60% |
| Next Qtr. | -41.20% | -- | -- | 10.50% |
| Current Year | -17.50% | -- | -- | 5.20% |
| Next Year | 38.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 0.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Evercore ISI Group: Outperform to Outperform | 3/20/2024 |
| Maintains | UBS: Buy to Buy | 3/15/2024 |
| Maintains | TD Cowen: Outperform to Outperform | 3/15/2024 |
| Maintains | Citigroup: Buy to Buy | 3/15/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/15/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/15/2024 |
Related Tickers
VKTX Viking Therapeutics, Inc.
63.42
-1.93%
CYTK Cytokinetics, Incorporated
67.55
+0.82%
AXSM Axsome Therapeutics, Inc.
67.90
+3.32%
ALT Altimmune, Inc.
6.91
+0.29%
AKRO Akero Therapeutics, Inc.
20.76
+1.22%
IOVA Iovance Biotherapeutics, Inc.
11.31
-3.50%
TGTX TG Therapeutics, Inc.
13.78
-1.50%
APLS Apellis Pharmaceuticals, Inc.
47.53
+0.04%
ARVN Arvinas, Inc.
34.72
+1.25%
RARE Ultragenyx Pharmaceutical Inc.
42.37
-2.33%